



Discovery of molecular nets inside heart muscles hold promise for new treatment

February 1 2018



Chondroitin sulfate (marked in red), virtually absent in healthy human heart tissue (upper panel), is found to accumulate in hearts of patients with heart failure, forming dense 'molecular nets' around the heart muscle cells (lower panel). Cell nuclei are marked in blue; scale bar represents 50 μm . Credit: NUHS

Researchers in Singapore have discovered that a group of molecules called chondroitin sulfate, normally found in connective tissues such as the cartilage, accumulates and causes inflammation in the hearts of patients with heart failure. The discovery is now published in *Circulation*, a journal from the American Heart Association.

Chondroitin sulfate is a polysaccharide, which is a long chain of sugar molecules, usually attached to certain proteins, forming molecular 'nets' outside cells. "In the rare [disease](#) known as mucopolysaccharidosis (MPS) type VI, patients have a genetic mutation that leads to systemic chondroitin sulfate accumulation. Because of this, MPS IV patients end up with multi-organ failure, including irregular heartbeats, enlarged heart muscles which may eventually result in heart failure. This evidence gives a very clear link between chondroitin sulfate accumulation and heart diseases," said Dr Zhao Rongrong from the NUHS' Cardiovascular Research Institute, who is the co-author in the study.

In this study, researchers found that diseased hearts, even from patients without MPS VI, were found to have chondroitin sulfate accumulation. Using the arylsulfatase B (ASB) enzyme, an approved treatment for MPS VI, it was demonstrated that fibrosis and disease progression was effectively treated in an animal model of [heart failure](#). This new treatment approach could potentially add to current treatment strategies, which include medicines such as beta-blockers and ACE-inhibitors.

"Understanding rare diseases gives us clues for how to treat common conditions. We have learned that [chondroitin](#) sulfate molecular nets don't only accumulate inside the [heart](#) muscle of patients with MPS VI. Heart failure patients without MPS VI also have these molecular nets, which can be targeted with a medicine that is already US FDA-approved. Targeting these molecular nets may bring a fresh new treatment approach for [patients](#) with this severe debilitating disease," said Associate Professor Roger Foo, who is the lead author in this study.

Cardiovascular disease (CVD) is a leading cause of death worldwide, with an estimated 17.7 million people dying from CVD in 2015, accounting for 31 percent of all global deaths. CVD also accounted for 29.6 percent of all deaths in Singapore in 2016.

More information: Rong-Rong Zhao et al. Targeting Chondroitin Sulfate Glycosaminoglycans to Treat Cardiac Fibrosis in Pathological Remodeling, *Circulation* (2018). [DOI: 10.1161/CIRCULATIONAHA.117.030353](#)

Provided by National University Health System

Citation: Discovery of molecular nets inside heart muscles hold promise for new treatment (2018, February 1) retrieved 6 May 2024 from <https://medicalxpress.com/news/2018-02-discovery-molecular-nets-heart-muscles.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
